Research Article
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes
Figure 1
Levels of serum antioxidants in individuals with type 1 diabetes, before and after treatment with empagliflozin 25 mg daily (EMPA), metformin 2000 mg daily (MET) or empagliflozin-metformin combination (EMPA-MET COMB), or in control (CTRL): (a) total antioxidative status (TAS), (b) glutathione peroxidase (GPx), and (c) superoxide dismutase (SOD). represents ; represents , and represents .
(a) |
(b) |
(c) |